Vnitr Lek 2025, 71(2):72-85 | DOI: 10.36290/vnl.2025.015

Diagnosis and treatment of infective endocarditis

Ondřej Ludka1, Miroslava Bendová2
1 Všeobecná interní klinika Fakultní nemocnice Brno a Lékařské fakulty Masarykovy univerzity Brno
2 Nemocniční lékárna Fakultní nemocnice Brno

The European Society of Cardiology published an updated guideline for the diagnosis and treatment of infective endocarditis in 2023 (1), which was subsequently adopted by the Czech Society of Cardiology (2). Unfortunately, the recommendations in the areas of antibiotic prophylaxis and treatment contain many shortcomings and errors (3), which is why three Czech professional societies have developed their own recommendations (4). The following text is a compilation of these documents, primarily intended for internists.

Keywords: antibiotics, cardiac implantable electronic device, cardiac surgery, complications, congenital heart disease, diagnosis, echocardiography, endocarditis, infection, prevention, prognosis, prosthetic heart valve, valve disease.

Accepted: March 18, 2025; Published: March 27, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ludka O, Bendová M. Diagnosis and treatment of infective endocarditis. Vnitr Lek. 2025;71(2):72-85. doi: 10.36290/vnl.2025.015.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023;44:3948-4042. Go to original source... Go to PubMed...
    2. Línkova H, Marek D, Mates M, et al. Doporučený postup Evropské kardiologické společnosti pro léčbu endokarditidy 2023. Delgado V, Ajmone Marsan N, de Waha S, et al. Překlad zkráceného dokumentu vypracovaný Pracovní skupinou pro chlopenní a vrozené srdeční vady České kardiologické společnosti, Českou společností kardiovaskularní chirurgie ČLS JEP a Společností infekčního lékařství ČLS JEP. Cor Vasa. 2024;66:112-168.
    3. Beneš J. Kritický komentář k textu "2023 ESC Guidelines for the Management of Endocarditis". Cor Vasa. 2024;66:455-465. Go to original source...
    4. Beneš J, Paterová P, Bauer L, et al. Antibiotická léčba infekční endokarditidy. Doporučený postup Společnosti infekčního lékařství ČLS JEP, Společnosti pro lékařskou mikrobiologii ČLS JEP a České odborné společnosti klinické farmacie ČLS JEP. Cor Vasa. 2024;66:632-643. Go to original source...
    5. Maeda K, Hirai Y, Nashi M, et al. Clinical features and antimicrobial susceptibility of oral bacteria isolated from the blood cultures of patients with infective endocarditis. J Dent Sci. 2022;17:870-875. Go to original source... Go to PubMed...
    6. Lafaurie GI, Noriega LA, Torres CC, et al. Impact of antibiotic prophylaxis on the incidence, nature, magnitude, and duration of bacteremia associated with dental procedures: A systematic review. J Am Dent Assoc. 2019;150:948.e4-959.e4. Go to original source... Go to PubMed...
    7. Rouse MS, Steckelberg JM, Brandt CM, et al. Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. Antimicrob Agents Chemother. 1997;41:1673-1676. Go to original source... Go to PubMed...
    8. Glauser MP, Francioli P. Successful prophylaxis against experimental streptococcal endocarditis with bacteriostatic antibiotics. J Infect Dis. 1982;146:806-810. Go to original source... Go to PubMed...
    9. Beneš J. Antibiotika: systematika, vlastnosti, použiti. Praha: Grada, 2018.
    10. Horstkotte D, Follath F, Gutschik E, et al. Guidelines on Prevention, Diagnosis and Treatment of Infective Endocarditis Executive Summary: The Task Force on Infective Endocarditis of the European Society of Cardiology. Eur Heart J. 2004;25:267-276. Go to original source... Go to PubMed...
    11. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J. 2015;36:3075-3128. Go to original source... Go to PubMed...
    12. Hoen B, Duval X, Durack DT. Prevention of Infective Endocarditis. In: Bennett JE, Dolin R, Blaser MJ (eds.). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th ed. Elsevier, 2020:1141-1150.
    13. Kaplan SL, Vallejo JG. Infective Endocarditis. In: Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ (eds.). Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 8th ed. Elsevier, 2019:256-270.
    14. Jindrák V, Hedlová D, Urbášková P, et al. Přístupy v používání antibiotik v klinické praxi. Antibiotická politika a prevence infekcí v nemocnici. Mladá fronta a. s.: Praha 2014. ISBN 978-80-204-2815-8.
    15. Holland TL, Baddour LM, Bayer AS, Hoen B, Miro JM, Fowler VG Jr. Infective endocarditis. Nat Rev Dis Primers. 2016 Sep 1;2:16059. doi: 10.1038/nrdp.2016. 59. Go to original source...
    16. Linhartová K, Beneš J, Gregor P. ESC Guidelines for the management of infective endocarditis. Summary document prepared by the Czech Society of Cardiology, Cor et Vasa. 2016;58:e107-e128. Go to original source...
    17. Falcone M, Russo A, Cassetta MI, et al. Variability of pharmacokinetic parametres in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? J. Infect. Chemother. 2013;19:732-739. Go to original source... Go to PubMed...
    18. Galar A, Munoz P, Valerio M, et al. Current use of daptomycin and systematic therapeutic drug monitoring: clinical experience in a tertiary care insitution. Int. J. Antimicro. Agents. 2019;53:40-48. Go to original source... Go to PubMed...
    19. Garreau R, Pham TT, Bourguignon L, et al. Daptomycin Exposure as a Risk Factor for Daptomycin-Induced Eosinophilic Pneumonia and Muscular Toxicity. Clin Infect Dis. 2023 Nov 17;77(10):1372-1380. doi: 10.1093/cid/ciad386. Go to original source... Go to PubMed...
    20. SPC. Cubicin, Cubicin, Summary of Produc Characteristics:https://prehledy.sukl.cz/prehled_leciv.html#.
    21. Crass RL, Powell KL, Huang AM. Daptomycin for the treatment of Staphylococcus aureus infections complicated by septic pulmonary emboli. Diagn Microbiol Infect Dis. 2019 Feb;93(2):131-135. doi: 10.1016/j.diagmicrobio.2018. 09. 004 Go to original source...
    22. Zainah H, Zervos M, Stephane W, Chamas Alhelo S, Alkhoury G, Weinmann A. Daptomycin Failure for Treatment of Pulmonary Septic Emboli in Native Tricuspid and Mitral Valve Methicillin-Resistant Staphylococcus aureus Endocarditis. Case Rep Infect Dis. 2013;653582. doi: 10.1155/2013/653582. Go to original source... Go to PubMed...
    23. Wallenburg E, Ter Heine R, de Lange DW, et al. High unbound flucloxacillin fraction in critically ill patients. J Antimicrob Chemother. 2021 Nov 12;76(12):3220-3228. doi: 10.1093/jac/dkab314. Go to original source... Go to PubMed...
    24. Kubíčková V, Vojtová V, Urbánek K. Farmakokinetické vlastnosti flukloxacilinu. Klinická farmakologie a farmacie. 2023;37(1):34-38. Go to original source...
    25. Rybak MJ, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists [published correction appears in Am J Health Syst Pharm. 2009;66(10):887]. Am J Health Syst Pharm. 2009;66(1):82-98. Available from https://www.ncbi.nlm.nih.gov/pubmed/19106348 Go to original source... Go to PubMed...
    26. Hanberger H, Edlund C, Furebring M, et al. Rational use of aminoglycosides - review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). Scandinavian journal of infectious diseases. 2013 Mar 1;45(3):161-75. Go to original source... Go to PubMed...
    27. Jackson J, Chen C, Buising K. Aminoglycosides: how should we use them in the 21st century? Current opinion in infectious diseases. 2013 Dec 1;26(6):516-25. Go to original source... Go to PubMed...
    28. Hong LT, Downes KJ, Fakhri Ravari A, et al. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2023 Aug;43(8):740-777. doi: 10.1002/phar.2842 Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.